Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,566 JPY | +0.29% | +5.28% | -7.15% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 146.88 and 32 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.15% | 17.89B | A | ||
+38.51% | 727B | C+ | ||
+33.05% | 599B | B | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+1.35% | 277B | C+ | ||
+16.00% | 243B | B+ | ||
+8.09% | 205B | B- | ||
-5.77% | 203B | A+ | ||
+6.19% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4503 Stock
- Ratings Astellas Pharma Inc.